Trial · NCT03285594
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18 | Placebo | -0.27 | Standard Error 0.073 | percentage of HbA1c | |
| Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18 | Sotagliflozin 200 mg | -0.72 | Standard Error 0.073 | percentage of HbA1c | |
| Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18 | Sotagliflozin 400 mg | -0.81 | Standard Error 0.056 | percentage of HbA1c | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 | Placebo | 12.882 | Standard Error 3.6045 | milligram per deciliter (mg/dL) | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 | Sotagliflozin 200 mg | -2.975 | Standard Error 3.6083 | milligram per deciliter (mg/dL) | |
| Change From Baseline in Fasting Plasma Glucose (FPG) at Week 18 | Sotagliflozin 400 mg | -8.949 | Standard Error 2.7550 | milligram per deciliter (mg/dL) | |
| Change From Baseline in Body Weight at Week 18 | Placebo | 0.36 | Standard Error 0.249 | kilogram (kg) | |
| Change From Baseline in Body Weight at Week 18 | Sotagliflozin 200 mg | -0.73 | Standard Error 0.250 | kilogram (kg) | |
| Change From Baseline in Body Weight at Week 18 | Sotagliflozin 400 mg | -1.37 | Standard Error 0.190 | kilogram (kg) | |
| Change From Baseline in Systolic Blood Pressure (SBP) for Participants With Baseline SBP ≥130 mmHg at Week 12 | Placebo | -4.67 | Standard Error 1.470 | mmHg | |
| Change From Baseline in Systolic Blood Pressure (SBP) for Participants With Baseline SBP ≥130 mmHg at Week 12 | Sotagliflozin 200 mg | -8.58 | Standard Error 1.447 | mmHg | |
| Change From Baseline in Systolic Blood Pressure (SBP) for Participants With Baseline SBP ≥130 mmHg at Week 12 | Sotagliflozin 400 mg | -8.50 | Standard Error 1.103 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants | Placebo | -0.21 | Standard Error 1.120 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants | Sotagliflozin 200 mg | -5.15 | Standard Error 1.117 | mmHg | |
| Change From Baseline in SBP at Week 12 for All Participants | Sotagliflozin 400 mg | -4.10 | Standard Error 0.867 | mmHg | |
| Change From Baseline in HbA1c at Week 52 | Placebo | 0.00 | Standard Error 0.279 | percentage of HbA1c | |
| Change From Baseline in HbA1c at Week 52 | Sotagliflozin 200 mg | -0.52 | Standard Error 0.152 | percentage of HbA1c | |
| Change From Baseline in HbA1c at Week 52 | Sotagliflozin 400 mg | -0.57 | Standard Error 0.114 | percentage of HbA1c | |
| Change From Baseline in Body Weight at Week 52 | Placebo | -0.18 | Standard Error 0.579 | kg | |
| Change From Baseline in Body Weight at Week 52 | Sotagliflozin 200 mg | -1.19 | Standard Error 0.620 | kg |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03285594/results